X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs SUN PHARMA - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK LTD SUN PHARMA MERCK LTD/
SUN PHARMA
 
P/E (TTM) x 48.0 36.0 133.1% View Chart
P/BV x 7.2 3.8 188.5% View Chart
Dividend Yield % 0.4 0.3 118.8%  

Financials

 MERCK LTD   SUN PHARMA
EQUITY SHARE DATA
    MERCK LTD
Dec-16
SUN PHARMA
Mar-18
MERCK LTD/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,060701 151.3%   
Low Rs623433 143.8%   
Sales per share (Unadj.) Rs632.4110.4 572.8%  
Earnings per share (Unadj.) Rs45.711.0 416.5%  
Cash flow per share (Unadj.) Rs62.317.2 361.7%  
Dividends per share (Unadj.) Rs11.002.00 550.0%  
Dividend yield (eoy) %1.30.4 370.5%  
Book value per share (Unadj.) Rs388.8158.8 244.9%  
Shares outstanding (eoy) m16.602,399.26 0.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.35.1 25.9%   
Avg P/E ratio x18.451.6 35.6%  
P/CF ratio (eoy) x13.532.9 41.0%  
Price / Book Value ratio x2.23.6 60.6%  
Dividend payout %24.118.2 132.1%   
Avg Mkt Cap Rs m13,9691,360,021 1.0%   
No. of employees `0001.617.8 8.9%   
Total wages/salary Rs m1,48753,671 2.8%   
Avg. sales/employee Rs Th6,631.914,890.9 44.5%   
Avg. wages/employee Rs Th939.23,017.1 31.1%   
Avg. net profit/employee Rs Th479.41,480.6 32.4%   
INCOME DATA
Net Sales Rs m10,498264,895 4.0%  
Other income Rs m2428,388 2.9%   
Total revenues Rs m10,741273,282 3.9%   
Gross profit Rs m1,13556,081 2.0%  
Depreciation Rs m27614,998 1.8%   
Interest Rs m05,176 0.0%   
Profit before tax Rs m1,10244,295 2.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-9,505 0.0%   
Tax Rs m3438,452 4.1%   
Profit after tax Rs m75926,338 2.9%  
Gross profit margin %10.821.2 51.1%  
Effective tax rate %31.119.1 163.2%   
Net profit margin %7.29.9 72.7%  
BALANCE SHEET DATA
Current assets Rs m6,410316,359 2.0%   
Current liabilities Rs m8,828198,643 4.4%   
Net working cap to sales %-23.044.4 -51.8%  
Current ratio x0.71.6 45.6%  
Inventory Days Days5895 60.8%  
Debtors Days Days38108 35.6%  
Net fixed assets Rs m1,406213,178 0.7%   
Share capital Rs m1662,399 6.9%   
"Free" reserves Rs m6,286378,606 1.7%   
Net worth Rs m6,455381,006 1.7%   
Long term debt Rs m017,721 0.0%   
Total assets Rs m8,828643,028 1.4%  
Interest coverage xNM9.6-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.20.4 288.7%   
Return on assets %8.64.9 175.4%  
Return on equity %11.86.9 170.1%  
Return on capital %17.110.0 170.4%  
Exports to sales %8.30-   
Imports to sales %21.00-   
Exports (fob) Rs m869NA-   
Imports (cif) Rs m2,209NA-   
Fx inflow Rs m95940,816 2.3%   
Fx outflow Rs m2,61230,143 8.7%   
Net fx Rs m-1,65310,673 -15.5%   
CASH FLOW
From Operations Rs m1,07039,072 2.7%  
From Investments Rs m-750-33,708 2.2%  
From Financial Activity Rs m-150-15,393 1.0%  
Net Cashflow Rs m171-7,359 -2.3%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 5.1 354.8%  
FIIs % 1.0 23.0 4.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 8.3 350.6%  
Shareholders   28,591 133,026 21.5%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK LTD With:   AJANTA PHARMA  GLENMARK PHARMA  SHASUN PHARMA  STRIDES SHASUN LTD  IPCA LABS  

Compare MERCK LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Over 450 Points Lower; IT and Energy Stocks Witness Selling(Closing)

Share markets in India continued their sell-off seen during the day and ended the trading session deep in the red. All sectoral indices traded on a negative note with stocks in the IT sector.

Related Views on News

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 19, 2018 | Updated on Sep 19, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

You Can Buy Select Auto Stocks Now for Big Long-Term Returns(The 5 Minute Wrapup)

Oct 17, 2018

Irrespective of the earnings hiccups, these businesses be setting new profit records.

This Market Crash could be the Biggest Wealth Creating Opportunity Since 2008(Profit Hunter)

Oct 8, 2018

While widespread fear is the friend of a value investor, serving up bargain purchases; personal fear is an investor's biggest enemy.

IPO Market Feels the Heat of the Market Crash(Sector Info)

Oct 12, 2018

The sentiments in primary market have also deteriorated amid the stock market correction. Most listed IPOs of 2018 are trading below their issue price.

Even If IL&FS Group Brought This Correction, this is Right Time to Buy & Sit Tight!(Chart Of The Day)

Oct 12, 2018

Even if IL&FS is the culprit, it may turn out to be a hero if you buy right and sit tight.

ICICI Prudential Manufacture In India Fund: A Make In India Prodigy, Should You Invest?(Outside View)

Oct 8, 2018

PersonalFN briefly explains if you should be investing in the NFO: ICICI Prudenetial Manufacture in India Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Oct 19, 2018 (Close)

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MERCK LTD 8-QTR ANALYSIS

COMPARE MERCK LTD WITH

MARKET STATS